Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8060) 8060
Publication (558) 558
Book Review (163) 163
Book Chapter (91) 91
Dissertation (21) 21
Conference Proceeding (18) 18
Magazine Article (9) 9
Book / eBook (3) 3
Paper (3) 3
Data Set (2) 2
Journal / eJournal (2) 2
Technical Report (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
atypical antipsychotics (5103) 5103
humans (4534) 4534
psychiatry (3928) 3928
schizophrenia (3819) 3819
male (3098) 3098
index medicus (3064) 3064
pharmacology & pharmacy (2706) 2706
female (2533) 2533
antipsychotic agents - therapeutic use (2504) 2504
neurosciences (2053) 2053
adult (1937) 1937
antipsychotic agents - adverse effects (1855) 1855
schizophrenia - drug therapy (1796) 1796
olanzapine (1751) 1751
risperidone (1539) 1539
clozapine (1466) 1466
middle aged (1438) 1438
double-blind (1403) 1403
animals (1308) 1308
clinical neurology (1284) 1284
haloperidol (1087) 1087
antipsychotic drugs (1060) 1060
antipsychotic agents - pharmacology (993) 993
treatment outcome (899) 899
antipsychotics (877) 877
atypical antipsychotic-drugs (874) 874
rats (865) 865
aged (817) 817
adolescent (801) 801
bipolar disorder (794) 794
drugs (773) 773
antipsychotic agents - administration & dosage (736) 736
atypical antipsychotic (698) 698
quetiapine (675) 675
drug therapy (666) 666
psychotropic drugs (666) 666
dopamine (646) 646
dose-response relationship, drug (604) 604
efficacy (575) 575
aripiprazole (570) 570
psychotic disorders - drug therapy (565) 565
neuroleptics (563) 563
analysis (546) 546
risk factors (522) 522
psychosis (507) 507
young adult (506) 506
risperidone - therapeutic use (501) 501
risk (482) 482
antipsychotic (478) 478
psychiatric status rating scales (472) 472
benzodiazepines - therapeutic use (444) 444
quetiapine fumarate (442) 442
rats, sprague-dawley (426) 426
bipolar disorder - drug therapy (424) 424
mental disorders (417) 417
prevalence (415) 415
schizophrenic psychology (401) 401
weight-gain (397) 397
time factors (390) 390
depression (387) 387
metabolic syndrome (382) 382
antidepressants (378) 378
dementia (376) 376
care and treatment (373) 373
serotonin (373) 373
retrospective studies (370) 370
clozapine - pharmacology (365) 365
double-blind method (362) 362
schizoaffective disorder (357) 357
research (349) 349
risperidone - adverse effects (349) 349
benzodiazepines - adverse effects (346) 346
prefrontal cortex (335) 335
drug therapy, combination (331) 331
medicine & public health (329) 329
child (328) 328
induced weight-gain (327) 327
comorbidity (326) 326
negative symptoms (323) 323
placebo (321) 321
dosage and administration (316) 316
schizophrenic-patients (316) 316
psychopharmacology (308) 308
clozapine - therapeutic use (306) 306
placebo-controlled trial (303) 303
atypical neuroleptics (300) 300
brain (300) 300
weight gain (299) 299
children (295) 295
internal medicine (294) 294
dibenzothiazepines - therapeutic use (292) 292
tardive-dyskinesia (292) 292
medicine, general & internal (291) 291
antipsychotic-drugs (289) 289
haloperidol - pharmacology (289) 289
health aspects (286) 286
safety (284) 284
piperazines - therapeutic use (282) 282
2nd-generation antipsychotics (280) 280
obesity (279) 279
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7563) 7563
German (187) 187
French (140) 140
Spanish (71) 71
Turkish (59) 59
Italian (42) 42
Russian (23) 23
Japanese (22) 22
Portuguese (22) 22
Polish (18) 18
Czech (16) 16
Dutch (13) 13
Korean (8) 8
Chinese (7) 7
Serbian (3) 3
Slovak (3) 3
Croatian (2) 2
Icelandic (2) 2
Persian (2) 2
Slovenian (2) 2
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Tardive dyskinesia and tardive dystonia with second-generation antipsychotics in non-elderly schizophrenic patients unexposed to first-generation antipsychotics a cross-sectional and retrospective study
by Ryu, Seunghyong and Yoo, Jae Hyun and Kim, Joo Hyun and Choi, Ji Sun and Baek, Ji Hyun and Ha, Kyooseob and Kwon, Jun Soo and Hong, Kyung Sue
Journal of Clinical Psychopharmacology, ISSN 0271-0749, 02/2015, Volume 35, Issue 1, pp. 13 - 21
This study investigates the clinical nature, prevalence rates, and associated factors of second-generation antipsychotic (SGA)-related tardive dyskinesia and... 
Schizophrenia | Tardive dystonia | Second-generation antipsychotics | Tardive dyskinesia | Obsessive-compulsive syndrome | TYPICAL ANTIPSYCHOTICS | PARKINSONISM | PSYCHIATRY | CLINICAL CHARACTERISTICS | SYMPTOMS | schizophrenia | PREVALENCE | tardive dystonia | ATYPICAL ANTIPSYCHOTICS | OBSESSIVE-COMPULSIVE DISORDER | AKATHISIA | second-generation antipsychotics | CURACAO EXTRAPYRAMIDAL SYNDROMES | PHARMACOLOGY & PHARMACY | obsessive-compulsive syndrome | tardive dyskinesia | ZIPRASIDONE | Dyskinesia, Drug-Induced - epidemiology | Cross-Sectional Studies | Antipsychotic Agents - adverse effects | Humans | Middle Aged | Movement Disorders - diagnosis | Male | Movement Disorders - epidemiology | Schizophrenia - epidemiology | Young Adult | Adult | Female | Retrospective Studies | Schizophrenia - drug therapy | Dyskinesia, Drug-Induced - diagnosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia Patients
by Nielsen, Jimmi and Skadhede, Søren and Correll, Christoph U
Neuropsychopharmacology, ISSN 0893-133X, 08/2010, Volume 35, Issue 9, pp. 1997 - 2004
Diabetes mellitus occurs in schizophrenia patients at higher rates than in the general population. Reasons for this elevated risk are poorly understood and... 
first-episode | olanzapine | clozapine | schizophrenia | diabetes | first-generation antipsychotics | METABOLIC SYNDROME | PSYCHIATRY | RISK | ILLNESS | MELLITUS | NEUROSCIENCES | ATYPICAL ANTIPSYCHOTICS | PREDICTORS | DISORDER | PHARMACOLOGY & PHARMACY | GLUCOSE-TOLERANCE | Confidence Intervals | Antipsychotic Agents - adverse effects | Humans | Risk Factors | Male | Antihypertensive Agents - therapeutic use | Incidence | Gene Expression Regulation - drug effects | Time Factors | Denmark | Adult | Female | Benzodiazepines - adverse effects | Retrospective Studies | Diabetes Mellitus, Type 2 - chemically induced | Schizophrenia - drug therapy | Cohort Studies | metabolic disorders | eating | epidemiology | psychopharmacology | antipsychotic naive | antipsychotics | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text International Consensus Study of Antipsychotic Dosing
by Gardner, David M and Murphy, Andrea L and O'Donnell, Heather and Centorrino, Franca and Baldessarini, Ross J
American Journal of Psychiatry, ISSN 0002-953X, 6/2010, Volume 167, Issue 6, pp. 686 - 693
ObjectivePotency equivalents for anti­psychotic drugs are required to guide clinical dosing and for designing and interpreting research studies. Available... 
MEDICATIONS | 2ND-GENERATION ANTIPSYCHOTICS | PSYCHIATRY | DRUGS | SCHIZOPHRENIA | RISPERIDONE | OCCUPANCY | ATYPICAL ANTIPSYCHOTICS | Antipsychotic Agents - administration & dosage | Delphi Technique | Drug Administration Schedule | Antipsychotic Agents - therapeutic use | Humans | International Cooperation | Psychotic Disorders - drug therapy | Consensus Development Conferences as Topic | Dosage and administration | Antipsychotic drugs
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Switching antipsychotics: Imaging the differential effect on the topography of postsynaptic density transcripts in antipsychotic-naïve vs. antipsychotic-exposed rats
by de Bartolomeis, Andrea and Marmo, Federica and Buonaguro, Elisabetta F and Latte, Gianmarco and Tomasetti, Carmine and Iasevoli, Felice
Progress in Neuropsychopharmacology & Biological Psychiatry, ISSN 0278-5846, 10/2016, Volume 70, pp. 24 - 38
The postsynaptic density (PSD) has been regarded as a functional switchboard at the crossroads of a dopamine–glutamate interaction, and it is putatively... 
Amisulpride | Treatment resistant schizophrenia | Homer | Haloperidol | ARC EXPRESSION | PSYCHIATRY | RECEPTOR OCCUPANCY | SYNAPTIC PLASTICITY | NEUROSCIENCES | ATYPICAL ANTIPSYCHOTICS | PREFRONTAL CORTEX | CLINICAL NEUROLOGY | DENDRITIC SPINES | DOPAMINE SUPERSENSITIVITY | GENE-EXPRESSION | PHARMACOLOGY & PHARMACY | LONG-TERM TREATMENT | HOMER PROTEINS | Disks Large Homolog 4 Protein | Sulpiride - pharmacology | Gene Expression - drug effects | Male | Intracellular Signaling Peptides and Proteins - metabolism | RNA, Messenger - metabolism | Corpus Striatum - metabolism | Cerebral Cortex - metabolism | Sulpiride - analogs & derivatives | Drug Resistance - physiology | Cytoskeletal Proteins - metabolism | Membrane Proteins - metabolism | Post-Synaptic Density - drug effects | Cerebral Cortex - drug effects | Post-Synaptic Density - metabolism | Haloperidol - pharmacology | Homer Scaffolding Proteins - metabolism | Injections, Intraperitoneal | Random Allocation | Rats, Sprague-Dawley | Nerve Tissue Proteins - metabolism | Animals | Corpus Striatum - drug effects | Antipsychotic Agents - pharmacology | Drug Substitution | Proteins | Glutamate
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Second‐generation antipsychotic effect on cognition in patients with schizophrenia—a meta‐analysis of randomized clinical trials
by Nielsen, R. E and Levander, S and Kjaersdam Telléus, G and Jensen, S. O. W and Østergaard Christensen, T and Leucht, S and Malmö University and Faculty of Health and Society and Criminology (KR)
Acta Psychiatrica Scandinavica, ISSN 0001-690X, 03/2015, Volume 131, Issue 3, pp. 185 - 196
Objective To investigate the effect of second‐generation antipsychotics on cognitive function in patients diagnosed with schizophrenia or schizoaffective... 
antipsychotics | schizophrenia | meta‐analysis | cognition | Schizophrenia | Antipsychotics | Cognition | Meta-analysis | SOCIAL COMPETENCE | COMPARATIVE EFFICACY | PSYCHIATRY | NEUROCOGNITIVE DEFICITS | meta-analysis | FOLLOW-UP | ATYPICAL ANTIPSYCHOTICS | 1ST-EPISODE SCHIZOPHRENIA | NEUROPSYCHOLOGICAL CHANGE | DOUBLE-BLIND | SHORT-TERM | WORKING-MEMORY | Antipsychotic Agents - therapeutic use | Antipsychotic Agents - adverse effects | Humans | Psychotic Disorders - psychology | Treatment Outcome | Clinical Trials as Topic | Psychotic Disorders - drug therapy | Schizophrenia - drug therapy | Cognition - drug effects | Schizophrenic Psychology | Olanzapine | Clozapine | Psychotropic drugs | Drug therapy | Medicine | NATURVETENSKAP | NATURAL SCIENCES
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Antipsychotics, Other Psychotropics, and the Risk of Death in Patients With Dementia: Number Needed to Harm
by Maust, Donovan T and Kim, Hyungjin Myra and Seyfried, Lisa S and Chiang, Claire and Kavanagh, Janet and Schneider, Lon S and Kales, Helen C
JAMA Psychiatry, ISSN 2168-622X, 05/2015, Volume 72, Issue 5, pp. 438 - 445
IMPORTANCE: Antipsychotic medications are associated with increased mortality in older adults with dementia, yet their absolute effect on risk relative to no... 
MORTALITY | MEDICATIONS | METAANALYSIS | EFFICACY | PSYCHIATRY | ALZHEIMERS-DISEASE | NEUROPSYCHIATRIC SYMPTOMS | OLDER-ADULTS | DRUGS | PLACEBO-CONTROLLED TRIALS | ATYPICAL ANTIPSYCHOTICS | United States - epidemiology | Antipsychotic Agents - adverse effects | Humans | Middle Aged | Male | Risk | Case-Control Studies | Dose-Response Relationship, Drug | Psychotropic Drugs - adverse effects | Dibenzothiazepines - adverse effects | Risperidone - adverse effects | Female | Registries | Retrospective Studies | Dementia - drug therapy | Quetiapine Fumarate | Veterans - psychology | Psychotropic Drugs - administration & dosage | Haloperidol - adverse effects | Dementia - mortality | Antipsychotic Agents - administration & dosage | Aged | Benzodiazepines - adverse effects | Veterans - statistics & numerical data | Antidepressive Agents - adverse effects | Dosage and administration | Antipsychotic drugs | Mortality | Analysis | Risk factors | Dementia | Veterans | Comorbidity | Americans | Survivors | Outpatient Treatment | Longitudinal Study | Psychiatric Disorders | Epidemiology | Benzodiazepines | Conventional Antipsychotics | Anticonvulsants | Cognitive Disorders | Etiology | Psychopharmacology | Opioids | Aging | Antidepressant Drugs | Atypical Antipsychotics | PTSD (ICD-9) | Negative Therapeutic Reaction
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Antipsychotic and antidepressive effects of second generation antipsychotics
: Two different pharmacological mechanisms?
by Möller, Hans-Jürgen
European Archives of Psychiatry and Clinical Neuroscience, ISSN 0940-1334, 6/2005, Volume 255, Issue 3, pp. 190 - 201
Second generation antipsychotics display antidepressive effects in schizophrenic patients that are more pronounced than those of traditional neuroleptics and... 
Neurology | Neurosciences | Medicine & Public Health | second generation antipsychotics | antidepressive efficacy | schizophrenia | depression | Psychiatry | Schizophrenia | Depression | Antidepressive efficacy | Second generation antipsychotics | STRIATUM IN-VIVO | RANDOMIZED CONTROLLED-TRIALS | SCHIZOPHRENIC-PATIENTS | NEGATIVE SYMPTOMS | PSYCHIATRY | ATYPICAL ANTIPSYCHOTICS | CLINICAL NEUROLOGY | NUCLEUS-ACCUMBENS | 5-HT1A RECEPTOR ACTIVATION | MEDIAL PREFRONTAL CORTEX | INDUCED DOPAMINE RELEASE | RAT-BRAIN | Receptors, Serotonin - physiology | Serotonin Agents - therapeutic use | Humans | Neurotransmitter Uptake Inhibitors - therapeutic use | Neurotransmitter Uptake Inhibitors - pharmacology | Schizophrenia - complications | Antidepressive Agents - therapeutic use | Depression - drug therapy | Animals | Antipsychotic Agents - therapeutic use | Depression - complications | Receptors, Dopamine D2 - physiology | Antidepressive Agents - pharmacology | Antipsychotic Agents - pharmacology | Schizophrenia - drug therapy | Dopamine - metabolism | Limbic System - drug effects | Depression, Mental | Antipsychotic drugs
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Metabolic side effects of antipsychotic drug treatment - pharmacological mechanisms
by Reynolds, Gavin P and Kirk, Shona L
Pharmacology and Therapeutics, ISSN 0163-7258, 01/2010, Volume 125, Issue 1, pp. 169 - 179
Obesity and metabolic syndrome, with increased risk of eventual cardiovascular disease and type II diabetes, are significant problems for patients receiving... 
Antipsychotic drugs | Diabetes | Hypothalamus | Metabolic syndrome | Weight gain | Leptin | 1ST-EPISODE SCHIZOPHRENIA | ATYPICAL ANTIPSYCHOTICS | 5-HT2C RECEPTOR GENE | INCREASED BODY-WEIGHT | INSULIN-RESISTANCE | PHARMACOLOGY & PHARMACY | INDUCED ANOREXIA | INDUCED WEIGHT-GAIN | BETA3 SUBUNIT GENE | CLINICAL-RESPONSE | C825T POLYMORPHISM | Genetic Predisposition to Disease | Neural Pathways - drug effects | Obesity - chemically induced | Antipsychotic Agents - adverse effects | Humans | Risk Factors | Metabolic Diseases - chemically induced | Metabolic Syndrome - chemically induced | Animals | Metabolic Diseases - metabolism | Signal Transduction - drug effects | Metabolic Diseases - genetics | Neural Pathways - metabolism | Diabetes Mellitus, Type 2 - chemically induced | Complications and side effects | Histamine | Prolactin | Cardiac patients | Physiological aspects | Intermedin | Glucose | Hormones | Dextrose
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Antipsychotic Polypharmacy in Schizophrenia
: Benefits and Risks
by Barnes, Thomas R. E and Paton, Carol
CNS Drugs, ISSN 1172-7047, 5/2011, Volume 25, Issue 5, pp. 383 - 399
Antipsychotic polypharmacy refers to the co-prescription of more than one antipsychotic drug for an individual patient. Surveys of prescribing in psychiatric... 
Pharmacotherapy | Neurology | Neurosciences | Medicine & Public Health | Psychiatry | Psychopharmacology | Prescribing | Schizophrenia | Antipsychotics | ADJUNCTIVE TREATMENT | REFRACTORY SCHIZOPHRENIA | PSYCHIATRIC-INPATIENTS | PSYCHIATRY | SCHIZOAFFECTIVE DISORDER | ATYPICAL ANTIPSYCHOTICS | CLINICAL NEUROLOGY | PRESCRIBING PRACTICES | TREATMENT-RESISTANT SCHIZOPHRENIA | 2ND-GENERATION ANTIPSYCHOTICS | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | OPEN-LABEL TRIAL | Guidelines as Topic | Polypharmacy | Antipsychotic Agents - therapeutic use | Antipsychotic Agents - adverse effects | Humans | Female | Male | Practice Patterns, Physicians | Psychotic Disorders - drug therapy | Schizophrenia - drug therapy | Drug Therapy, Combination | Surveys | Complications and side effects | Antipsychotic drugs | Patients | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: A meta-analysis
by Carbon, Maren and Hsieh, Cheng-Hsi and Kane, John M and Correll, Christoph U
Journal of Clinical Psychiatry, ISSN 0160-6689, 03/2017, Volume 78, Issue 3, pp. e264 - e278
Objective: Comparison of tardive dyskinesia (TD) prevalence during contemporaneous treatment with first-generation antipsychotics (FGAs) and/or... 
MOVEMENT-DISORDERS | INJECTABLE RISPERIDONE | SEROTONIN RECEPTOR | RISK-FACTORS | SCHIZOPHRENIC-PATIENTS | CLOZAPINE TREATMENT | PSYCHIATRY | EAST-ASIA | EXTRAPYRAMIDAL SYMPTOMS | PSYCHOLOGY, CLINICAL | ATYPICAL ANTIPSYCHOTICS | MALADAPTIVE PLASTICITY | Tardive Dyskinesia - epidemiology | Cross-Sectional Studies | Antipsychotic Agents - therapeutic use | Antipsychotic Agents - adverse effects | Humans | Psychotic Disorders - drug therapy | Tardive Dyskinesia - prevention & control | Psychotic Disorders - epidemiology
Journal Article